Pharmacokinetics and Biodistribution of Nanomaterials

Nanotoxicology: Progress toward Nanomedicine

Volumn , Issue , 2014, Pages 135-152

  Riviere, Jim E ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84992204899     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16562-14     Document Type: Chapter

References (56)

1. Riviere JE, Tran CL. Pharmacokinetics of nanomaterials. In Monteiro-Riviere NA, Tran CL, eds. Nanotoxicology: Characterization, Dosing and Health Effects. New York: Informa, 2007: 127-40.
2. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv. Colloid Interface Sci. 2007; 134-135: 167-74.
3. Nel AE, Madler L, Velego D, Xia T, Hoek EMV, Somasundaran P, Klaessig F, Castranova V, Thompson M. Understanding biophysiochemical interactions at the nano-bio interface. Nat. Mater. 2009; 8: 543-57.
4. Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 2012; 7: 779-86.
5. Gajewicz A, Rasulev B, Dinadayalane TC, Urbaszek P, Puzyn T, Leszczynska D, Leszczynska J. Advancing risk assessment of engineered nanomaterials: Application of computational approaches. Adv. Drug Deliv. Rev. 2012; 64: 1663-93. doi:10.1016/j.addr.2012.05.014.
6. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008; 5: 496-504.
7. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 2012; 52: 481-503.
8. Riviere JE. Pharmacokinetics of nanomaterials: An overview of carbon nanotubes, fullerenes and quantum dots. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009; 1: 26-34.
9. Yang W, Peters JI, Williams RO. Inhaled nanoparticles-A current review. Int. J. Pharm. 2008; 356: 239-47.
10. Adair JH, Parette MP, Altinoglu EI, Kester M. Nanoparticulate alternatives for drug delivery. ACS Nano. 2010; 4: 4967-70.
11. Des Rieux A, Fieves V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control Release. 2006; 116: 1-27.
12. Monteiro-Riviere NA, Riviere JE. Interactions of nanomaterials with the skin: Aspects of absorption and biodistribution. Nanotoxicology. 2009; 3: 188-93.
13. Monteiro-Riviere NA, Wiench K, Landsiedel R, Schulte S, Inman AO, Riviere JE. Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB-exposed skin: An in vitro and in vivo study. Toxicol. Sci. 2011; 123: 264-80.
14. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schultz H, Oberdörster G, Ziesenis A. Translocation of ultrafine insoluble iridium particles from the lung epithelium to extrapulmonary organs is size dependent but very low. J. Toxicol. Environ. Health. A. 2002; 65: 1513-30.
15. Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J. Control Release 2010; 141: 277-99.
16. Walkey CD, Chan WCW. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 2012; 41: 2780-99.
17. Cedervall T, Lynch I, Foy M, Berggård T, Donnelly SC, Cagney G, Linse S, Dawson KA. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew. Chem. Int. Ed. Engl. 2007; 46: 5754-6.
18. Pedersen MB, Zhou X, Larsen EKU, Sorensen US, Kjems J. Curvature of synthetic and natural surfaces is an important target in classical pathway complement activation. J. Immunol. 2010; 184: 1931-45.
19. Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tissue uptake of GMI-containing liposomes. Biochim. Biophys. Acta. 1992; 1104: 95-101.
20. Moreira JN, Gaspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer. Biochim. Biophys. Acta. 2001; 1515: 167-76.
21. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2007; 2: 249-55.
22. Gentile F, Ferrari M, Decuzzi P. The transport of nanoparticles in blood vessels: The effect of vessel permeability and blood rheology. Ann. Biomed. Eng. 2008; 36: 254-61.
23. Yu T, Hubbard D, Ray A, Ghandehari H. In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J. Control Release. 2012; 163: 46-54.
24. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. Liposome clearance in mice: The effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm. 2002; 240: 95-102.
25. Almeida JPM, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine (Lond). 2011; 6: 815-35.
26. Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Variables influencing interactions of untargeted quantum dot, nanoparticles with skin cells and identification of biochemical modulators. Nano Lett. 2007; 7:1344-8.
27. Shannahan JH, Brown JM, Chen R, Ke PC, Lai X, Mitra S, Witzmann FA. Comparison of nanotube protein corona composition in cell culture media. Small. 2013; 9: 2171-81. doi:10.1002/smll.201202243.
28. Monteiro-Riviere NA, Samberg ME, Oldenburg SJ, Riviere JE. Protein binding modulates the cellular uptake of silver nanoparticles into human cells: Implications for in vitro to in vivo extrapolations. Toxicol. Lett. 2013; 220: 286-93.
29. Yim YS, Choi JS, Jang SB, Kim GT, Park K, Kim CH, Cheon J, Kim DG. Pharmacokinetic properties and tissue storage of FITC conjugated SA-MnMEIO nanoparticles in mice. Curr. Appl. Physiol. 2009; 9: E304-7.
30. Gopee NV, Roberts DW, Webb P, Cozart CR, Siitonen PH, Warbritton, AR, Yu WW, Colvin VL, Walker NJ, Howard PC. Migration of intradermally injected quantum dots to sentinel organs in mice. Toxicol. Sci. 2007; 98: 249-57.
31. Soltesz EG, Kim S, Laurence RG, DeGrand AM, Parungo CP, Dor DM, Cohn LH, Bawendi MG, Frangioni JV, Mihaljevic T. Interoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann. Thorac. Surg. 2005; 79: 269-77.
32. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nat. Biotechnol. 2007; 25: 1165-70.
33. Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, Vlasova II et al. Carbon nanotubes degraded by neutrophil myeloperoxidase induces less pulmonary inflammation. Nat Nanotechnol. 2010; 5: 354-59.
34. Ette EI, Williams PJ. Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken: Wiley, 2007.
35. Riviere JE. Comparative Pharmacokinetics: Principles, Techniques and Applications, 2nd ed. Ames: Wiley-Blackwell, 2011.
36. Shargel L, Wu-Pong S, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics, 5th ed. New York: McGraw Hill, 2005.
37. Reddy MA, Yang RSH, Clewell HJ, Andersen ME. Physiologically Based Pharmacokinetic Modeling. Hoboken: Wiley, 2005.
38. Riviere JE, Bowman KF, Monteiro-Riviere NA, Dix LP, Carver MP. The isolated perfused porcine skin flap (IPPSF). I. A novel in vitro model for percutaneous absorption and cutaneous toxicology studies. Fundam. Appl. Toxicol. 1986; 7: 444-53.
39. Riviere JE, Monteiro-Riviere NA. The isolated perfused porcine skin flap as an in vitro model for percutaneous absorption and cutaneous toxicology. Crit. Rev. Toxicol. 1991; 21: 329-44.
40. Lee HA, Imran M, Monteiro-Riviere NA, Colvin VL, Wu W, Riviere JE. Biodistribution of quantum dot nanoparticles in perfused skin: Evidence of coating dependency and periodicity in arterial extraction. Nano Lett. 2007; 7: 2865-70.
41. Leavens TL, Xia XR, Lee HY, Monteiro-Riviere NA, Brooks JD, Riviere JE. Evaluation of perfused porcine skin as a model system to quantitate tissue distribution of fullerene nanoparticles. Toxicol. Lett. 2010; 197: 1-6.
42. Leavens TL, Monteiro-Riviere NA, Inman AO, Brooks JD, Oldenburg SJ, Riviere, JE. In vitro biodistribution of silver nanomaterial in isolated perfused porcine skin flaps. J. Appl. Toxicol. 2012; 32: 913-9.
43. Riviere JE, Leavens TL, Brooks JD, Monteiro-Riviere NA. Acute vascular effects of nanoparticle infusion in isolated perfused skin. Nanomedicine. 2012; 8: 428-31.
44. Rogers RA, Riviere JE. Pharmacologic modulation of the cutaneous vasculature in the isolated perfused porcine skin flap (IPPSF). J. Pharm. Sci. 1994; 83: 1682-89.
45. Yu T, Greish K, McGill LD, Ray A, Ghandehari H. Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: Their vasculature effects and tolerance threshold. ACS Nano. 2012; 6: 2289-301.
46. Li M, Al-Jamal K, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano. 2010; 11: 6303-17.
47. Lin P, Chen JW, Chang LW, Wu JP, Redding L, Chang H, Yeh, TK et al. Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. Environ. Sci. Technol. 2008; 42: 6264-70.
48. Yang RS, Chang LW, Wu JP, Tsai MH, Wang HJ, Kuo YC, Yeh TK, Yang CS, Lin P. Persistent tissue kinetics and redistribution of nanoparticles, Quantum Dot 705, in Mice: ICP-MS Quantitative Assessment. Environ. Health Perspect. 2007; 115: 1339-43.
49. Lee HA, Leavens T, Mason SE, Monteiro-Riviere NA, Riviere JE. Comparison of quantum dot biodistribution with blood-flow limited physiologically based pharmacokinetic model. Nano Lett. 2009; 9: 794-9.
50. Lankveld DPK, Ooman AG, Krystek P, Neigh A, Troost de Jong A, Noorlander CW, Van Eijkeren JCH, Geertsma RE, de Jong WH. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials. 2010; 31: 8350-61.
51. Liu J, Wang Z, Liu FD, Kanes AB, Hurt RH. Chemical transformation of nanosilver in biological environments. ACS Nano. 2012; 6: 9887-99.
52. Xia XR, Monteiro-Riviere NA, Mathur S, Oldenberg S, Fadell B, Riviere JE. Mapping the surface adsorption forces of nanomaterials in biological systems using the biological surface adsorption index (BSAI) approach. ACS Nano. 2011; 5: 9074-81.
53. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat. Nanotechnol. 2010; 5: 671-5.
54. Dell’Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One. 2010; 5: e10949.
55. Dell’Orco D, Lundqvist M, Cedervall T, Linse S. Delivery success rate of engineered nanoparticles in the presence of the protein corona: A systems-level screening. Nanomedicine. 2012; 8: 1271-81.
56. Sahneh FD, Scoglio C, Riviere JE. Dynamics of nanoparticle-protein corona complex formation: Analytical results from population balance equations. PLoS One. 2013; 8: e64690.